REGENXBIO Inc. (RGNX) Stock

REGENXBIO Inc. is a leading clinical-stage biotechnology company specializing in the development of innovative gene therapy product candidates. Founded in 2008 and headquartered in Rockville, Maryland, the company focuses on leveraging its proprietary NAV Technology Platform. This platform utilizes adeno-associated virus vectors to deliver therapeutic genes to cells, aiming to correct genetic defects or induce cells to produce therapeutic proteins and antibodies targeted at various diseases.

At the forefront of its pipeline is RGX-314, currently in Phase III clinical trials for the treatment of wet age-related macular degeneration. In addition to RGX-314, REGENXBIO is advancing several other promising candidates through clinical development stages. These include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late-infantile neuronal ceroid lipofuscinosis type II (preclinical stage), RGX-202 for Duchenne muscular dystrophy (Phase I/II), and RGX-381 for ocular manifestations of CLN2 disease (preclinical stage).

Beyond its internal pipeline, REGENXBIO licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies, fostering collaborations and expanding the application of gene therapy across various therapeutic areas. The company has also established a strategic collaboration and license agreement with Neurimmune AG to jointly develop novel gene therapies, underscoring its commitment to advancing transformative treatments.

Driven by innovation and scientific excellence, REGENXBIO Inc. continues to pioneer the development of gene therapies aimed at addressing significant unmet medical needs. With a robust pipeline and strategic partnerships, the company remains dedicated to advancing the field of gene therapy and improving outcomes for patients worldwide.